Nominations to the Advisory Committee on Blood and Tissue Safety and Availability, 4923-4924 [2015-01682]
Download as PDF
mstockstill on DSK4VPTVN1PROD with NOTICES
Federal Register / Vol. 80, No. 19 / Thursday, January 29, 2015 / Notices
Tissue Safety and Availability
(ACBTSA) will hold a meeting. The
meeting will be open to the public.
DATES: The meeting will take place
Tuesday April 7, 2105, from 8:00 a.m.–
4:00 p.m. and Wednesday April 8, 2015,
from 8:00 a.m.–3:30 p.m.
ADDRESSES: NIH Conference Room, 5635
Fishers Lane, Rockville, MD 20892.
FOR FURTHER INFORMATION CONTACT: Mr.
James Berger, Designated Federal Officer
for the ACBTSA, Senior Advisor for
Blood and Tissue Policy, Office of the
Assistant Secretary for Health,
Department of Health and Human
Services, 1101 Wootton Parkway, Suite
250, Rockville, MD 20852. Phone: (240)
453–8803; Fax (240) 453–8456; Email
ACBTSA@hhs.gov.
SUPPLEMENTARY INFORMATION: The
ACBTSA provides advice to the
Secretary through the Assistant
Secretary for Health. The Committee
advises on a range of policy issues to
include: (1) Identification of public
health issues through surveillance of
blood and tissue safety issues with
national biovigilance data tools; (2)
identification of public health issues
that affect availability of blood, blood
products, and tissues; (3) broad public
health, ethical and legal issues related to
the safety of blood, blood products, and
tissues; (4) the impact of various
economic factors (e.g., product cost and
supply) on safety and availability of
blood, blood products, and tissues; (5)
risk communications related to blood
transfusion and tissue transplantation;
and (6) identification of infectious
disease transmission issues for blood,
organs, blood stem cells and tissues.
The Committee has met regularly since
its establishment in 1997.
The ACBTSA has made previous
recommendations on the need to
improve tissue tracking and traceability.
These recommendations focused on
tracking adverse events, creating a
unique identifier for each donor, and
improving patient outcomes. Past
recommendations made by the ACBTSA
may be viewed at www.hhs.gov/
bloodsafety.
The focus of the meeting will be to
address current issues in tracking and
traceability of tissue recovered from
deceased donors. The discussion will
focus on pertinent federal and state
regulations, other mechanisms that
impact tissue tracking and traceability,
and current gaps in this area. Presenters
will represent a wide range of
government and non-government
stakeholders, including federal agencies,
accreditation organizations, tissue and
eye banks, healthcare facilities, and
medical practitioners.
VerDate Sep<11>2014
18:16 Jan 28, 2015
Jkt 235001
The public will have an opportunity
to present their views to the Committee
during a public comment session
scheduled for April 8, 2015. Comments
will be limited to five minutes per
speaker and must be pertinent to the
discussion. Pre-registration is required
for participation in the public comment
session. Any member of the public who
would like to participate in this session
is encouraged to contact the Designated
Federal Officer at his/her earliest
convenience to register for time (limited
to 5 minutes) ; registration must be
completed prior to close of business on
April 1, 2015. If it is not possible to
provide 30 copies of the material to be
distributed at the meeting, then
individuals are requested to provide a
minimum of one (1) copy of the
document(s) to be distributed prior to
the close of business on April 1, 2015.
It is also requested that any member of
the public who wishes to provide
comments to the Committee utilizing
electronic data projection submit the
necessary material to the Designated
Federal Officer prior to the close of
business on April 1, 2015.
Dated: January 22, 2015.
James J. Berger,
Senior Advisor for Blood and Tissue Safety
Policy.
[FR Doc. 2015–01680 Filed 1–28–15; 8:45 am]
BILLING CODE 4150–41–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Nominations to the Advisory
Committee on Blood and Tissue Safety
and Availability
Office of the Secretary, Office
of the Assistant Secretary for Health,
Department of Health and Human
Services.
ACTION: Notice.
AGENCY:
The Office of Assistant
Secretary for Health (OASH) is seeking
nominations of qualified individuals to
be considered for appointment as
members of the Advisory Committee on
Blood and Tissue Safety and
Availability (ACBTSA). ACBTSA is a
Federal advisory committee within the
Department of Health and Human
Services. Management support for the
activities of this Committee is the
responsibility of the OASH. The
qualified individuals will be nominated
to the Secretary of Health and Human
Services for consideration of
appointment as members of the
ACBTSA. Members of the Committee,
including the Chair, are appointed by
the Secretary. Members are invited to
SUMMARY:
PO 00000
Frm 00071
Fmt 4703
Sfmt 4703
4923
serve on the Committee for up to fouryear terms.
DATES: All nominations must be
received no later than 4:00 p.m. EDT on
March 2, 2015, at the address listed
below.
All nominations should be
mailed or delivered to Mr. James Berger,
Senior Advisor for Blood and Tissue
Policy; Office of Assistant Secretary for
Health; Department of Health and
Human Services; 1101 Wootton
Parkway, Suite 250; Rockville, MD
20852. Telephone: (240) 453–8803; Fax
(240) 453–8456; Email ACBTSA@
hhs.gov.
ADDRESSES:
Mr.
James Berger, Senior Advisor for Blood
and Tissue Policy. Contact information
for Mr. Berger is provided above.
A copy of the Committee charter and
roster of the current membership can be
obtained by contacting Mr. Berger or by
accessing the ACBTSA Web site at
https://www.hhs.gov/bloodsafety. https://
www.hhs.gov/bloodsafety.
SUPPLEMENTARY INFORMATION: The
ACBTSA shall provide advice to the
Secretary through the Assistant
Secretary for Health. The Committee
shall advise on a range of policy issues
to include: (1) Identification of public
health issues through surveillance of
blood and tissue safety issues with
national biovigilance data tools; (2)
identification of public health issues
that affect availability of blood, blood
products, and tissues; (3) broad public
health, ethical and legal issues related to
the safety of blood, blood products, and
tissues; (4) the impact of various
economic factors (e.g., product cost and
supply) on safety and availability of
blood, blood products, and tissues; (5)
risk communications related to blood
transfusion and tissue transplantation;
and (6) identification of infectious
disease transmission issues for blood,
organs, blood stem cells and tissues.
The Committee consists of 23 voting
members. The Committee composition
includes 14 public members, including
the Chair, and nine (9) individuals
designated to serve as official
representative members. The public
members are selected from state and
local organizations, patient advocacy
groups, provider organizations,
academic researchers, ethicists,
physicians, surgeons, scientists, risk
communication experts, consumer
advocates, and from among
communities of persons who are
frequent recipients of blood or blood
products or who have received tissues
or organs. The nine individuals who are
appointed as official representatives are
FOR FURTHER INFORMATION CONTACT:
E:\FR\FM\29JAN1.SGM
29JAN1
4924
Federal Register / Vol. 80, No. 19 / Thursday, January 29, 2015 / Notices
mstockstill on DSK4VPTVN1PROD with NOTICES
selected to serve the interests of the
blood, blood products, tissue and organ
professional organizations or business
sectors. The representative members are
selected from the following groups: The
AABB (formerly the American
Association of Blood Banks); American
Association of Tissue Banks; Eye Bank
Association of America; Association of
Organ Procurement Organizations; and
one of either the American National Red
Cross or America’s Blood Centers on a
rotating basis. The Committee
composition can include additional
representation from either the plasma
protein fraction community or a trade
organization; a manufacturer of blood,
plasma, or other tissue/organ test kits; a
manufacturer of blood, plasma or other
tissue/organ equipment; a major
hospital organization; or a major
hospital accreditation organization.
Where more than one company
produces a specified product or process,
representatives from those companies
shall rotate on the same schedule as
public members.
All ACBTSA members are authorized
to receive the prescribed per diem
allowance and reimbursement for travel
expenses that are incurred to attend
meetings and conduct Committeerelated business, in accordance with
Standard Government Travel
Regulations. Individuals who are
appointed to serve as public members
are authorized also to receive a stipend
for attending Committee meetings and
to carry out other Committee-related
business. Individuals who are appointed
to serve as representative members for a
particular interest group or industry are
not authorized to receive a stipend for
the performance of these duties.
This announcement is to solicit
nominations of qualified candidates to
fill nine public member positions that
are scheduled to be vacated on the
ACBTSA.
Nominations
In accordance with the charter,
persons nominated for appointment as
members of the ACBTSA should be
among authorities knowledgeable in
blood banking, tissue banking,
transfusion medicine, organ or tissue
transplantation, plasma therapies,
transfusion and transplantation safety,
bioethics, and/or related disciplines.
Nominations should be typewritten. The
following information should be
included in the package of material
submitted for each individual being
nominated for consideration of
appointment: (a) The name, return
address, daytime telephone number and
affiliation(s) of the individual being
nominated, the basis for the individual’s
VerDate Sep<11>2014
18:16 Jan 28, 2015
Jkt 235001
nomination, the category for which the
individual is being nominated, and a
statement bearing an original signature
of the nominated individual that, if
appointed, he or she is willing to serve
as a member of the Committee; (b) the
name, return address, and daytime
telephone number at which the
nominator may be contacted.
Organizational nominators must
identify a principal contact person in
addition to the contact; and (c) a copy
of a current curriculum vitae or resume
for the nominated individual.
Individuals can nominate themselves
for consideration of appointment to the
Committee. All nominations must
include the required information.
Incomplete nominations will not be
processed for consideration. The letter
from the nominator and certification of
the nominated individual must bear
original signatures; reproduced copies
of these signatures are not acceptable.
The Department is legally required to
ensure that the membership of HHS
Federal advisory committees is fairly
balanced in terms of points of view
represented and the functions to be
performed by the advisory committee.
Every effort is made to ensure that the
views of women, all ethnic and racial
groups, and people with disabilities are
represented on HHS Federal Advisory
committees and, therefore, the
Department encourages nominations of
qualified candidates from these groups.
The Department also encourages
geographic diversity in the composition
of the committee. Appointment to this
Committee shall be made without
discrimination on the basis of age, race,
ethnicity, gender, sexual orientation,
disability, and cultural, religious, or
socioeconomic status.
The Standards of Ethical Conduct for
Employees of the Executive Branch are
applicable to individuals who are
appointed as public members of Federal
advisory committees. Individuals
appointed to serve as public members of
Federal advisory committees are
classified as special government
employees (SGEs). The federal conflict
of interest laws are applicable to SGEs.
Therefore, individuals appointed to
serve as public members of the ACBTSA
are subject to an ethics review. The
ethics review is conducted to determine
if the individual has any interests and/
or activities in the private sector that
may conflict with performance of their
official duties as a member of the
Committee. Individuals appointed to
serve as public members of the
committee will be required to disclose
information regarding financial
holdings, consultancies, and research
grants and/or contracts.
PO 00000
Frm 00072
Fmt 4703
Sfmt 4703
Dated: January 22, 2015.
James J. Berger,
Senior Advisor for Blood and Tissue Policy.
[FR Doc. 2015–01682 Filed 1–28–15; 8:45 am]
BILLING CODE 4150–41–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[30-Day–15–0931]
Agency Forms Undergoing Paperwork
Reduction Act Review
The Centers for Disease Control and
Prevention (CDC) has submitted the
following information collection request
to the Office of Management and Budget
(OMB) for review and approval in
accordance with the Paperwork
Reduction Act of 1995. The notice for
the proposed information collection is
published to obtain comments from the
public and affected agencies.
Written comments and suggestions
from the public and affected agencies
concerning the proposed collection of
information are encouraged. Your
comments should address any of the
following: (a) Evaluate whether the
proposed collection of information is
necessary for the proper performance of
the functions of the agency, including
whether the information will have
practical utility; (b) Evaluate the
accuracy of the agencies estimate of the
burden of the proposed collection of
information, including the validity of
the methodology and assumptions used;
(c) Enhance the quality, utility, and
clarity of the information to be
collected; (d) Minimize the burden of
the collection of information on those
who are to respond, including through
the use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submission of
responses; and (e) Assess information
collection costs.
To request additional information on
the proposed project or to obtain a copy
of the information collection plan and
instruments, call (404) 639–7570 or
send an email to omb@cdc.gov. Written
comments and/or suggestions regarding
the items contained in this notice
should be directed to the Attention:
CDC Desk Officer, Office of Management
and Budget, Washington, DC 20503 or
by fax to (202) 395–5806. Written
comments should be received within 30
days of this notice.
E:\FR\FM\29JAN1.SGM
29JAN1
Agencies
[Federal Register Volume 80, Number 19 (Thursday, January 29, 2015)]
[Notices]
[Pages 4923-4924]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2015-01682]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Nominations to the Advisory Committee on Blood and Tissue Safety
and Availability
AGENCY: Office of the Secretary, Office of the Assistant Secretary for
Health, Department of Health and Human Services.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Office of Assistant Secretary for Health (OASH) is seeking
nominations of qualified individuals to be considered for appointment
as members of the Advisory Committee on Blood and Tissue Safety and
Availability (ACBTSA). ACBTSA is a Federal advisory committee within
the Department of Health and Human Services. Management support for the
activities of this Committee is the responsibility of the OASH. The
qualified individuals will be nominated to the Secretary of Health and
Human Services for consideration of appointment as members of the
ACBTSA. Members of the Committee, including the Chair, are appointed by
the Secretary. Members are invited to serve on the Committee for up to
four-year terms.
DATES: All nominations must be received no later than 4:00 p.m. EDT on
March 2, 2015, at the address listed below.
ADDRESSES: All nominations should be mailed or delivered to Mr. James
Berger, Senior Advisor for Blood and Tissue Policy; Office of Assistant
Secretary for Health; Department of Health and Human Services; 1101
Wootton Parkway, Suite 250; Rockville, MD 20852. Telephone: (240) 453-
8803; Fax (240) 453-8456; Email ACBTSA@hhs.gov.
FOR FURTHER INFORMATION CONTACT: Mr. James Berger, Senior Advisor for
Blood and Tissue Policy. Contact information for Mr. Berger is provided
above.
A copy of the Committee charter and roster of the current
membership can be obtained by contacting Mr. Berger or by accessing the
ACBTSA Web site at https://www.hhs.gov/bloodsafety. https://www.hhs.gov/bloodsafety.
SUPPLEMENTARY INFORMATION: The ACBTSA shall provide advice to the
Secretary through the Assistant Secretary for Health. The Committee
shall advise on a range of policy issues to include: (1) Identification
of public health issues through surveillance of blood and tissue safety
issues with national biovigilance data tools; (2) identification of
public health issues that affect availability of blood, blood products,
and tissues; (3) broad public health, ethical and legal issues related
to the safety of blood, blood products, and tissues; (4) the impact of
various economic factors (e.g., product cost and supply) on safety and
availability of blood, blood products, and tissues; (5) risk
communications related to blood transfusion and tissue transplantation;
and (6) identification of infectious disease transmission issues for
blood, organs, blood stem cells and tissues.
The Committee consists of 23 voting members. The Committee
composition includes 14 public members, including the Chair, and nine
(9) individuals designated to serve as official representative members.
The public members are selected from state and local organizations,
patient advocacy groups, provider organizations, academic researchers,
ethicists, physicians, surgeons, scientists, risk communication
experts, consumer advocates, and from among communities of persons who
are frequent recipients of blood or blood products or who have received
tissues or organs. The nine individuals who are appointed as official
representatives are
[[Page 4924]]
selected to serve the interests of the blood, blood products, tissue
and organ professional organizations or business sectors. The
representative members are selected from the following groups: The AABB
(formerly the American Association of Blood Banks); American
Association of Tissue Banks; Eye Bank Association of America;
Association of Organ Procurement Organizations; and one of either the
American National Red Cross or America's Blood Centers on a rotating
basis. The Committee composition can include additional representation
from either the plasma protein fraction community or a trade
organization; a manufacturer of blood, plasma, or other tissue/organ
test kits; a manufacturer of blood, plasma or other tissue/organ
equipment; a major hospital organization; or a major hospital
accreditation organization. Where more than one company produces a
specified product or process, representatives from those companies
shall rotate on the same schedule as public members.
All ACBTSA members are authorized to receive the prescribed per
diem allowance and reimbursement for travel expenses that are incurred
to attend meetings and conduct Committee-related business, in
accordance with Standard Government Travel Regulations. Individuals who
are appointed to serve as public members are authorized also to receive
a stipend for attending Committee meetings and to carry out other
Committee-related business. Individuals who are appointed to serve as
representative members for a particular interest group or industry are
not authorized to receive a stipend for the performance of these
duties.
This announcement is to solicit nominations of qualified candidates
to fill nine public member positions that are scheduled to be vacated
on the ACBTSA.
Nominations
In accordance with the charter, persons nominated for appointment
as members of the ACBTSA should be among authorities knowledgeable in
blood banking, tissue banking, transfusion medicine, organ or tissue
transplantation, plasma therapies, transfusion and transplantation
safety, bioethics, and/or related disciplines. Nominations should be
typewritten. The following information should be included in the
package of material submitted for each individual being nominated for
consideration of appointment: (a) The name, return address, daytime
telephone number and affiliation(s) of the individual being nominated,
the basis for the individual's nomination, the category for which the
individual is being nominated, and a statement bearing an original
signature of the nominated individual that, if appointed, he or she is
willing to serve as a member of the Committee; (b) the name, return
address, and daytime telephone number at which the nominator may be
contacted. Organizational nominators must identify a principal contact
person in addition to the contact; and (c) a copy of a current
curriculum vitae or resume for the nominated individual.
Individuals can nominate themselves for consideration of
appointment to the Committee. All nominations must include the required
information. Incomplete nominations will not be processed for
consideration. The letter from the nominator and certification of the
nominated individual must bear original signatures; reproduced copies
of these signatures are not acceptable.
The Department is legally required to ensure that the membership of
HHS Federal advisory committees is fairly balanced in terms of points
of view represented and the functions to be performed by the advisory
committee. Every effort is made to ensure that the views of women, all
ethnic and racial groups, and people with disabilities are represented
on HHS Federal Advisory committees and, therefore, the Department
encourages nominations of qualified candidates from these groups. The
Department also encourages geographic diversity in the composition of
the committee. Appointment to this Committee shall be made without
discrimination on the basis of age, race, ethnicity, gender, sexual
orientation, disability, and cultural, religious, or socioeconomic
status.
The Standards of Ethical Conduct for Employees of the Executive
Branch are applicable to individuals who are appointed as public
members of Federal advisory committees. Individuals appointed to serve
as public members of Federal advisory committees are classified as
special government employees (SGEs). The federal conflict of interest
laws are applicable to SGEs. Therefore, individuals appointed to serve
as public members of the ACBTSA are subject to an ethics review. The
ethics review is conducted to determine if the individual has any
interests and/or activities in the private sector that may conflict
with performance of their official duties as a member of the Committee.
Individuals appointed to serve as public members of the committee will
be required to disclose information regarding financial holdings,
consultancies, and research grants and/or contracts.
Dated: January 22, 2015.
James J. Berger,
Senior Advisor for Blood and Tissue Policy.
[FR Doc. 2015-01682 Filed 1-28-15; 8:45 am]
BILLING CODE 4150-41-P